ClinicalTrials.gg
CompletedNCT03170609Updated Jul 2, 2019Results posted

A Phase 1/2, Randomized, Placebo-controlled, Observer-blinded Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A Multivalent Group B Streptococcus Vaccine In Healthy Adults 18 To 49 Years Of Age

A Phase 2 interventional study of Multivalent group B streptococcus vaccine and Placebo in Group B Streptococcal Infections, sponsored by Pfizer. Completed at 4 sites in United States. Open to participants aged 18 Years to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-07-02.

Sponsored by Pfizer · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
365
Allocation
Randomized
Ages
18 Years to 49 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies in Streptococcal Infections with a site in United States — 1 open to participants now, 2 under way, none of them phase 3. Streptococcal Infections · United States.

Enrollment
9th of 17
365 · median 365
Started
2017
the only one that year
Phase 2
10 of 24
none open now
Registered
16th of 24
by date
Lead sponsor
2 of 24
Pfizer

Among the 24 studies in Streptococcal Infections with a site in United States, this one is the 9th largest by enrollment of the 17 interventional ones that give a count, is the only one that started in 2017, is one of 10 in phase 2, and was the 16th registered.

Streptococcal Infections

147 studies on the registry are indexed under Streptococcal Infections; 14 are open to participants now.

Browse Streptococcal Infections studies →

Open to participants now

1 of the 24 studies in Streptococcal Infections with a site in United States is open now. Recruiting first, the newest first:

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 10 Streptococcal Infections studies recruiting now, 6 (60%) set no upper age limit and 3 (30%) stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 49 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Streptococcal Infections with a site in United States, or all of them as a file.
02

Study summary

This is the Phase 1/2 first-in-human, randomized, placebo-controlled, observer-blinded study evaluating the investigational multivalent group B streptococcus vaccine. Healthy adults aged 18 to 49 years of age with no history of group B streptococcal vaccination will be randomized to receive either a single intramuscular dose of multivalent group B streptococcus vaccine (various formulations at 3 dose levels) or a placebo (saline control).

03

Conditions studied

  • Group B Streptococcal Infections
04

Who can participate

Ages eligible
18 Years to 49 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy adults (male and female) 18 to 49 years of age at enrollment who are determined by medical history, physical examination, and clinical judgment of the investigator to be eligible for inclusion in the study.
  2. Negative urine pregnancy test at Visit 1 for all female subjects who are of .

Exclusion criteria

Exclusion Criteria:

  1. Male subjects and female subjects of who are unwilling or unable to use a highly effective method of as outlined in this protocol for at least 3 months after the last dose of product.
  2. Acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study. Chronic medical conditions include , chronic virus (HBV) infection (HBV surface antigen positive), and/or virus infection.
  3. History of severe adverse reaction and/or severe allergic reaction (eg, anaphylaxis) to any vaccine.
  4. History of microbiologically proven invasive disease caused by group B streptococcus (Streptococcus agalactiae).
  5. Previous vaccination with any licensed or investigational group B streptococcus vaccine, or planned receipt during the subject's participation in the study (through the last blood draw).
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
365 participants (actual)

Study arms

  • Experimental
    Lowest dose formulation a

    Multivalent group B streptococcus vaccine

    Biological: Multivalent group B streptococcus vaccine

  • Experimental
    Middle dose formulation a

    Multivalent group B streptococcus vaccine

    Biological: Multivalent group B streptococcus vaccine

  • Experimental
    Highest dose formulation a

    Multivalent group B streptococcus vaccine

    Biological: Multivalent group B streptococcus vaccine

  • Experimental
    Lowest dose formulation b

    Multivalent group B streptococcus vaccine

    Biological: Multivalent group B streptococcus vaccine

  • Experimental
    Middle dose formulation b

    Multivalent group B streptococcus vaccine

    Biological: Multivalent group B streptococcus vaccine

  • Experimental
    Highest dose formulation b

    Multivalent group B streptococcus vaccine

    Biological: Multivalent group B streptococcus vaccine

  • Placebo comparator
    Placebo

    Saline control

    Biological: Placebo

Interventions

  • BiologicalMultivalent group B streptococcus vaccine

    Various formulations at three dose levels

  • BiologicalPlacebo

    Saline Control

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Clinical Laboratory Abnormalities at 1-Week After Vaccination as Measured by Food and Drug Administration (FDA) Grade

    Hemoglobin:Grade(G)1: 11-13.5g/dL, G2:9.5-12.4g/dL,G3:8-10.4 g/dL, G4:\<8.0 g/dL; leukocyte increase:G1: 10.8-15\*10\^9/Liter\[L\],G2:\>15-20\*10\^9/L, G3:\>20-25\*10\^9/L, G4:\>25\*10\^9/L,leukocyte decrease: G1: 2.5-3.5\*10\^9/L, G2: 1.5-\<2.5\*10\^9/L, G3: 1-\<1.5\*10\^9/L, G4:\<1\*10\^9/L; neutrophil decrease:G1: 1.5-2\*10\^9/L, G2:1-\<1.5\*10\^9/L, G3:0.5-\<1\*10\^9/L,G4:\<0.5\*10\^9/L; platelets:G1: 125-140\*10\^9/L, G2:100-124\*10\^9/L, G3:25-99\*10\^9/L, G4:\<25\*10\^9/L; eosinophils: G1: 0.65-1.5\*10\^9/L, G2:\>1.5-5\*10\^9/L, G3:\>5\*10\^9/L, G4: hypereosinophilic;alanine aminotransferase,aspartate aminotransferase:G1: 1.1-2.5 \*ULN, G2:2.6-5.0\*ULN, G3:5.1-10\*ULN, G4:\>10\*ULN; alkaline phosphatase:G1: 1.1-2\*ULN, G2:2.1-3\*ULN, G3:3.1-10\*ULN, G4:\>10\*ULN; Bilirubin:G1: 1.1-1.5\*ULN, G2: 1.26-2\*ULN,G3: 1.51-3.0\*ULN,G4:\>1.75\*ULN;blood urea nitrogen:G1:23-26mg/dL,G2:27-31mg/dL,G3:\>31mg/dL, G4:dialysis;creatinine:G1:1.5-1.7mg/dL,G2:1.8-2mg/dL,G3:2.1-2.5 mg/dL,G4:dialysis.Categories with\>=1 participant with abnormality are reported only.

    Time frame: 1 week after vaccination

  2. Percentage of Participants With Local Reactions by Maximum Severity Within 14 Days After Vaccination

    Local reactions were collected by using an e-diary and included redness, swelling and pain at injection site. Redness and swelling were graded as: mild (2.5-5.0 centimeter \[cm\]), moderate (greater than \[\>\] 5.0-10.0 cm) and severe (\>10.0 cm), grade 4 for redness (necrosis or exfoliative dermatitis) and grade 4 for swelling (necrosis). Pain at injection site was graded as: mild (did not interfere with activity), moderate (repeated use of nonnarcotic pain reliever \>24 hours or interfered with activity), severe (any use of narcotic pain reliever or prevented daily activity which resulted in missed days of work or school or was otherwise incapacitating, or included use of narcotics for analgesia), and grade 4 (required emergency room visit or hospitalization). The maximum severity (highest grading) of each location reaction within 14 days of vaccination was derived.

    Time frame: Within 14 days after vaccination

  3. Percentage of Participants With Systemic Events by Maximum Severity Within 14 Days After Vaccination

    Fever:38.0-38.4 degree Celsius (C),38.5-38.9 degree C,39.0-40.0 degree C,\>40.0 degree C;nausea/vomiting:mild(not interfered with activity/1-2times in 24 hours\[hr\]),moderate(some interference with activity/\>2times in 24hr),severe(prevented daily activity;required intravenous hydration); diarrhea:mild(2-3 loose stools in 24hr),moderate(4-5 loose stools in 24hr),severe(\>=6 loose stools in 24 hr); headache:mild(not interfered with activity),moderate(repeated use of non-narcotic pain reliever \>24 hr/some interference with activity),severe(significant;any use of narcotic pain reliever/prevented daily activity);fatigue,muscle and joint pain:mild(not interfered with activity), moderate(some interference with activity),severe(significant;prevented daily activity).Prevented daily activity=missed days of work, school/otherwise incapacitating/use of narcotics for analgesia.Nausea/vomiting,diarrhea,headache,fatigue/tiredness,muscle and joint pain: grade 4=emergency room visit or hospitalization.

    Time frame: Within 14 days after vaccination

  4. Percentage of Participants With Adverse Events (AEs) Within 1 Month After Vaccination

    An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly or that was considered to be an important medical event. AEs included both non-serious AEs and SAEs.

    Time frame: Within 1 month after vaccination

  5. Percentage of Participants With Serious Adverse Events (SAEs) Within 6 Month After Vaccination

    An AE was any untoward medical occurrence in a participant in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly or that was considered to be an important medical event.

    Time frame: Within 6 months after vaccination

  6. Percentage of Participants With Medically Attended Adverse Events (MAEs) Within 6 Months After Vaccination

    An AE was any untoward medical occurrence in a participant in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly or that was considered to be an important medical event. An MAE was defined as a non serious AE (AE other than SAE) that resulted in an evaluation at a medical facility.

    Time frame: Within 6 months after vaccination

Secondary outcomes

  1. GBS6 Serotype-Specific Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) at 1 Month After Vaccination

    Serotypes used for evaluation were: Ia, Ib, II, III, IV, and V.

    Time frame: 1 month after vaccination

07

Results

Posted Jul 2, 2019

Participant flow

Participant flow — Overall Study
MilestoneGBS6 5 Microgram With Aluminum PhosphateGBS6 5 Microgram Without Aluminum PhosphateGBS6 10 Microgram With Aluminum PhosphateGBS6 10 Microgram Without Aluminum PhosphateGBS6 20 Microgram With Aluminum PhosphateGBS6 20 Microgram Without Aluminum PhosphatePlacebo
Started53525252525252
Vaccinated52525252525252
Completed50504650515051
Not completed3262121
Withdrew: Death0010000
Withdrew: Withdrawal by subject1200001
Withdrew: Lost to follow-up1052110
Withdrew: Other1000010

Outcome measures

PrimaryPercentage of Participants With Clinical Laboratory Abnormalities at 1-Week After Vaccination as Measured by Food and Drug Administration (FDA) Grade

Hemoglobin:Grade(G)1: 11-13.5g/dL, G2:9.5-12.4g/dL,G3:8-10.4 g/dL, G4:\<8.0 g/dL; leukocyte increase:G1: 10.8-15\*10\^9/Liter\[L\],G2:\>15-20\*10\^9/L, G3:\>20-25\*10\^9/L, G4:\>25\*10\^9/L,leukocyte decrease: G1: 2.5-3.5\*10\^9/L, G2: 1.5-\<2.5\*10\^9/L, G3: 1-\<1.5\*10\^9/L, G4:\<1\*10\^9/L; neutrophil decrease:G1: 1.5-2\*10\^9/L, G2:1-\<1.5\*10\^9/L, G3:0.5-\<1\*10\^9/L,G4:\<0.5\*10\^9/L; platelets:G1: 125-140\*10\^9/L, G2:100-124\*10\^9/L, G3:25-99\*10\^9/L, G4:\<25\*10\^9/L; eosinophils: G1: 0.65-1.5\*10\^9/L, G2:\>1.5-5\*10\^9/L, G3:\>5\*10\^9/L, G4: hypereosinophilic;alanine aminotransferase,aspartate aminotransferase:G1: 1.1-2.5 \*ULN, G2:2.6-5.0\*ULN, G3:5.1-10\*ULN, G4:\>10\*ULN; alkaline phosphatase:G1: 1.1-2\*ULN, G2:2.1-3\*ULN, G3:3.1-10\*ULN, G4:\>10\*ULN; Bilirubin:G1: 1.1-1.5\*ULN, G2: 1.26-2\*ULN,G3: 1.51-3.0\*ULN,G4:\>1.75\*ULN;blood urea nitrogen:G1:23-26mg/dL,G2:27-31mg/dL,G3:\>31mg/dL, G4:dialysis;creatinine:G1:1.5-1.7mg/dL,G2:1.8-2mg/dL,G3:2.1-2.5 mg/dL,G4:dialysis.Categories with\>=1 participant with abnormality are reported only.

Time frame:
1 week after vaccination
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Laboratory Abnormalities at 1-Week After Vaccination as Measured by Food and Drug Administration (FDA) Grade
percentage of participantsGBS6 5 Microgram With Aluminum PhosphateGBS6 5 Microgram Without Aluminum PhosphateGBS6 10 Microgram With Aluminum PhosphateGBS6 10 Microgram Without Aluminum PhosphateGBS6 20 Microgram With Aluminum PhosphateGBS6 20 Microgram Without Aluminum PhosphatePlacebo
Hemoglobin: Grade 106.312.5006.30
Hemoglobin: Grade 26.3000000
Platelets: Grade 1006.36.7000
Leukocyte decrease:Grade 16.36.300000
Leukocyte increase: Grade 1000006.30
Leukocyte increase: Grade 20000004.2
Neutrophils decrease(Absolute): Grade 16.318.80006.30
Neutrophils decrease (Absolute): Grade 200006.300
Blood urea nitrogen: Grade 10000004.2
Blood urea nitrogen: Grade 2000006.30
Aspartate aminotransferase: Grade 100006.300
Aspartate aminotransferase: Grade 306.300000
Alanine aminotransferase: Grade 106.30012.500
Bilirubin in presence of normal AST and ALT:Grade1006.30000
Alkaline phosphate: Grade 1006.30000
PrimaryPercentage of Participants With Local Reactions by Maximum Severity Within 14 Days After Vaccination

Local reactions were collected by using an e-diary and included redness, swelling and pain at injection site. Redness and swelling were graded as: mild (2.5-5.0 centimeter \[cm\]), moderate (greater than \[\>\] 5.0-10.0 cm) and severe (\>10.0 cm), grade 4 for redness (necrosis or exfoliative dermatitis) and grade 4 for swelling (necrosis). Pain at injection site was graded as: mild (did not interfere with activity), moderate (repeated use of nonnarcotic pain reliever \>24 hours or interfered with activity), severe (any use of narcotic pain reliever or prevented daily activity which resulted in missed days of work or school or was otherwise incapacitating, or included use of narcotics for analgesia), and grade 4 (required emergency room visit or hospitalization). The maximum severity (highest grading) of each location reaction within 14 days of vaccination was derived.

Time frame:
Within 14 days after vaccination
Reported as:
Number · percentage of participants
Percentage of Participants With Local Reactions by Maximum Severity Within 14 Days After Vaccination
percentage of participantsGBS6 5 Microgram With Aluminum PhosphateGBS6 5 Microgram Without Aluminum PhosphateGBS6 10 Microgram With Aluminum PhosphateGBS6 10 Microgram Without Aluminum PhosphateGBS6 20 Microgram With Aluminum PhosphateGBS6 20 Microgram Without Aluminum PhosphatePlacebo
Pain:Any53.8 (39.5 to 67.8)32.7 (20.3 to 47.1)48.1 (34.0 to 62.4)38.5 (25.3 to 53.0)51.9 (37.6 to 66.0)25.0 (14.0 to 38.9)15.4 (6.9 to 28.1)
Pain:Mild51.9 (37.6 to 66.0)28.8 (17.1 to 43.1)44.2 (30.5 to 58.7)36.5 (23.6 to 51.0)42.3 (28.7 to 56.8)19.2 (9.6 to 32.5)13.5 (5.6 to 25.8)
Pain:Moderate1.9 (0.0 to 10.3)3.8 (0.5 to 13.2)3.8 (0.5 to 13.2)1.9 (0.0 to 10.3)9.6 (3.2 to 21.0)5.8 (1.2 to 15.9)1.9 (0.0 to 10.3)
Pain:Severe0 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)
Pain:Grade 40 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)
Redness:Any0 (0.0 to 6.8)3.8 (0.5 to 13.2)1.9 (0.0 to 10.3)0 (0.0 to 6.8)5.8 (1.2 to 15.9)0 (0.0 to 6.8)0 (0.0 to 6.8)
Redness:Mild0 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)5.8 (1.2 to 15.9)0 (0.0 to 6.8)0 (0.0 to 6.8)
Redness:Moderate0 (0.0 to 6.8)3.8 (0.5 to 13.2)1.9 (0.0 to 10.3)0 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)
Redness:Severe0 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)
Redness:Grade 40 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)
Swelling:Any0 (0.0 to 6.8)5.8 (1.2 to 15.9)1.9 (0.0 to 10.3)3.8 (0.5 to 13.2)5.8 (1.2 to 15.9)0 (0.0 to 6.8)0 (0.0 to 6.8)
Swelling:Mild0 (0.0 to 6.8)1.9 (0.0 to 10.3)1.9 (0.0 to 10.3)3.8 (0.5 to 13.2)5.8 (1.2 to 15.9)0 (0.0 to 6.8)0 (0.0 to 6.8)
Swelling:Moderate0 (0.0 to 6.8)3.8 (0.5 to 13.2)0 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)
Swelling:Severe0 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)
Swelling:Grade 40 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)
PrimaryPercentage of Participants With Systemic Events by Maximum Severity Within 14 Days After Vaccination

Fever:38.0-38.4 degree Celsius (C),38.5-38.9 degree C,39.0-40.0 degree C,\>40.0 degree C;nausea/vomiting:mild(not interfered with activity/1-2times in 24 hours\[hr\]),moderate(some interference with activity/\>2times in 24hr),severe(prevented daily activity;required intravenous hydration); diarrhea:mild(2-3 loose stools in 24hr),moderate(4-5 loose stools in 24hr),severe(\>=6 loose stools in 24 hr); headache:mild(not interfered with activity),moderate(repeated use of non-narcotic pain reliever \>24 hr/some interference with activity),severe(significant;any use of narcotic pain reliever/prevented daily activity);fatigue,muscle and joint pain:mild(not interfered with activity), moderate(some interference with activity),severe(significant;prevented daily activity).Prevented daily activity=missed days of work, school/otherwise incapacitating/use of narcotics for analgesia.Nausea/vomiting,diarrhea,headache,fatigue/tiredness,muscle and joint pain: grade 4=emergency room visit or hospitalization.

Time frame:
Within 14 days after vaccination
Reported as:
Number · percentage of participants
Percentage of Participants With Systemic Events by Maximum Severity Within 14 Days After Vaccination
percentage of participantsGBS6 5 Microgram With Aluminum PhosphateGBS6 5 Microgram Without Aluminum PhosphateGBS6 10 Microgram With Aluminum PhosphateGBS6 10 Microgram Without Aluminum PhosphateGBS6 20 Microgram With Aluminum PhosphateGBS6 20 Microgram Without Aluminum PhosphatePlacebo
Fever:>=38.0 degree C0 (0.0 to 6.8)0 (0.0 to 6.8)1.9 (0.0 to 10.3)0 (0.0 to 6.8)1.9 (0.0 to 10.3)1.9 (0.0 to 10.3)1.9 (0.0 to 10.3)
Fever:38.0 to 38.4 degree C0 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)1.9 (0.0 to 10.3)0 (0.0 to 6.8)
Fever:38.5 to 38.9 degree C0 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)1.9 (0.0 to 10.3)0 (0.0 to 6.8)1.9 (0.0 to 10.3)
Fever:39.0 to 40.0 degree C0 (0.0 to 6.8)0 (0.0 to 6.8)1.9 (0.0 to 10.3)0 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)
Fever:>40.0 degree C0 (0.0 to 6.8)0 (0.0 to 6.8)0 (0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)
Nausea/vomiting: Any13.5 (5.6 to 25.8)5.8 (1.2 to 15.9)11.5 (4.4 to 23.4)17.3 (8.2 to 30.3)9.6 (3.2 to 21.0)11.5 (4.4 to 23.4)21.2 (11.1 to 34.7)
Nausea/vomiting: Mild9.6 (3.2 to 21.0)3.8 (0.5 to 13.2)9.6 (3.2 to 21.0)11.5 (4.4 to 23.4)7.7 (2.1 to 18.5)9.6 (3.2 to 21.0)13.5 (5.6 to 25.8)
Nausea/vomiting: Moderate3.8 (0.5 to 13.2)1.9 (0.0 to 10.3)1.9 (0.0 to 10.3)5.8 (1.2 to 15.9)1.9 (0.0 to 10.3)1.9 (0.0 to 10.3)7.7 (2.1 to 18.5)
Nausea/vomiting: Severe0 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)
Nausea/vomiting: Grade 40 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)
Diarrhea:Any13.5 (5.6 to 25.8)21.2 (11.1 to 34.7)13.5 (5.6 to 25.8)21.2 (11.1 to 34.7)21.2 (11.1 to 34.7)17.3 (8.2 to 30.3)11.5 (4.4 to 23.4)
Diarrhea:Mild11.5 (4.4 to 23.4)21.2 (11.1 to 34.7)11.5 (4.4 to 23.4)13.5 (5.6 to 25.8)19.2 (9.6 to 32.5)11.5 (4.4 to 23.4)5.8 (1.2 to 15.9)
Diarrhea:Moderate1.9 (0.0 to 10.3)0 (0.0 to 6.8)1.9 (0.0 to 10.3)3.8 (0.5 to 13.2)0 (0.0 to 6.8)5.8 (1.2 to 15.9)5.8 (1.2 to 15.9)
Diarrhea:Severe0 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)3.8 (0.5 to 13.2)1.9 (0.0 to 10.3)0 (0.0 to 6.8)0 (0.0 to 6.8)
Diarrhea:Grade 40 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)
Headache:Any40.4 (27.0 to 54.9)36.5 (23.6 to 51.0)32.7 (20.3 to 47.1)38.5 (25.3 to 53.0)40.4 (27.0 to 54.9)30.8 (18.7 to 45.1)42.3 (28.7 to 56.8)
Headache:Mild26.9 (15.6 to 41.0)21.2 (11.1 to 34.7)15.4 (6.9 to 28.1)11.5 (4.4 to 23.4)28.8 (17.1 to 43.1)11.5 (4.4 to 23.4)23.1 (12.5 to 36.8)
Headache:Moderate13.5 (5.6 to 25.8)13.5 (5.6 to 25.8)15.4 (6.9 to 28.1)25.0 (14.0 to 38.9)11.5 (4.4 to 23.4)17.3 (8.2 to 30.3)15.4 (6.9 to 28.1)
Headache:Severe0 (0.0 to 6.8)1.9 (0.0 to 10.3)1.9 (0.0 to 10.3)1.9 (0.0 to 10.3)0 (0.0 to 6.8)1.9 (0.0 to 10.3)3.8 (0.5 to 13.2)
Headache:Grade 40 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)
Fatigue/tiredness: Any42.3 (28.7 to 56.8)32.7 (20.3 to 47.1)34.6 (22.0 to 49.1)26.9 (15.6 to 41.0)50.0 (35.8 to 64.2)38.5 (25.3 to 53.0)34.6 (22.0 to 49.1)
Fatigue/tiredness: Mild19.2 (9.6 to 32.5)11.5 (4.4 to 23.4)9.6 (3.2 to 21.0)7.7 (2.1 to 18.5)25.0 (14.0 to 38.9)19.2 (9.6 to 32.5)9.6 (3.2 to 21.0)
Fatigue/tiredness: Moderate23.1 (12.5 to 36.8)21.2 (11.1 to 34.7)21.2 (11.1 to 34.7)15.4 (6.9 to 28.1)25.0 (14.0 to 38.9)19.2 (9.6 to 32.5)19.2 (9.6 to 32.5)
Fatigue/tiredness: Severe0 (0.0 to 6.8)0 (0.0 to 6.8)3.8 (0.5 to 13.2)3.8 (0.5 to 13.2)0 (0.0 to 6.8)0 (0.0 to 6.8)5.8 (1.2 to 15.9)
Fatigue/tiredness:Grade 40 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)
Muscle pain:Any17.3 (8.2 to 30.3)25.0 (14.0 to 38.9)19.2 (9.6 to 32.5)19.2 (9.6 to 32.5)19.2 (9.6 to 32.5)23.1 (12.5 to 36.8)19.2 (9.6 to 32.5)
Muscle pain:Mild9.6 (3.2 to 21.0)17.3 (8.2 to 30.3)7.7 (2.1 to 18.5)11.5 (4.4 to 23.4)13.5 (5.6 to 25.8)17.3 (8.2 to 30.3)5.8 (1.2 to 15.9)
Muscle pain:Moderate7.7 (2.1 to 18.5)7.7 (2.1 to 18.5)9.6 (3.2 to 21.0)7.7 (2.1 to 18.5)5.8 (1.2 to 15.9)5.8 (1.2 to 15.9)11.5 (4.4 to 23.4)
Muscle pain:Severe0 (0.0 to 6.8)0 (0.0 to 6.8)1.9 (0.0 to 10.3)0 (0.0 to 6.8)0 (0.0 to 6.8)0.0 (0.0 to 6.8)1.9 (0.0 to 10.3)
Muscle pain:Grade 40 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)
Joint pain:Any13.5 (5.6 to 25.8)9.6 (3.2 to 21.0)13.5 (5.6 to 25.8)9.6 (3.2 to 21.0)13.5 (5.6 to 25.8)11.5 (4.4 to 23.4)5.8 (1.2 to 15.9)
Joint pain:Mild9.6 (3.2 to 21.0)5.8 (1.2 to 15.9)3.8 (0.5 to 13.2)7.7 (2.1 to 18.5)9.6 (3.2 to 21.0)9.6 (3.2 to 21.0)1.9 (0.0 to 10.3)
Joint pain:Moderate3.8 (0.5 to 13.2)3.8 (0.5 to 13.2)9.6 (3.2 to 21.0)1.9 (0.0 to 10.3)3.8 (0.5 to 13.2)1.9 (0.0 to 10.3)3.8 (0.5 to 13.2)
Joint pain:Severe0 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)
Joint pain:Grade 40 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)0 (0.0 to 6.8)
PrimaryPercentage of Participants With Adverse Events (AEs) Within 1 Month After Vaccination

An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly or that was considered to be an important medical event. AEs included both non-serious AEs and SAEs.

Time frame:
Within 1 month after vaccination
Reported as:
Number · percentage of participants
Percentage of Participants With Adverse Events (AEs) Within 1 Month After Vaccination
percentage of participantsGBS6 5 Microgram With Aluminum PhosphateGBS6 5 Microgram Without Aluminum PhosphateGBS6 10 Microgram With Aluminum PhosphateGBS6 10 Microgram Without Aluminum PhosphateGBS6 20 Microgram With Aluminum PhosphateGBS6 20 Microgram Without Aluminum PhosphatePlacebo
Percentage of Participants With Adverse Events (AEs) Within 1 Month After Vaccination19.2 (9.6 to 32.5)5.8 (1.2 to 15.9)19.2 (9.6 to 32.5)13.5 (5.6 to 25.8)26.9 (15.6 to 41.0)28.8 (17.1 to 43.1)21.2 (11.1 to 34.7)
PrimaryPercentage of Participants With Serious Adverse Events (SAEs) Within 6 Month After Vaccination

An AE was any untoward medical occurrence in a participant in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly or that was considered to be an important medical event.

Time frame:
Within 6 months after vaccination
Reported as:
Number · percentage of participants
Percentage of Participants With Serious Adverse Events (SAEs) Within 6 Month After Vaccination
percentage of participantsGBS6 5 Microgram With Aluminum PhosphateGBS6 5 Microgram Without Aluminum PhosphateGBS6 10 Microgram With Aluminum PhosphateGBS6 10 Microgram Without Aluminum PhosphateGBS6 20 Microgram With Aluminum PhosphateGBS6 20 Microgram Without Aluminum PhosphatePlacebo
Percentage of Participants With Serious Adverse Events (SAEs) Within 6 Month After Vaccination1.9 (0.0 to 10.3)0 (0.0 to 6.8)1.9 (0.0 to 10.3)0 (0.0 to 6.8)1.9 (0.0 to 10.3)0 (0.0 to 6.8)0 (0.0 to 6.8)
PrimaryPercentage of Participants With Medically Attended Adverse Events (MAEs) Within 6 Months After Vaccination

An AE was any untoward medical occurrence in a participant in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly or that was considered to be an important medical event. An MAE was defined as a non serious AE (AE other than SAE) that resulted in an evaluation at a medical facility.

Time frame:
Within 6 months after vaccination
Reported as:
Number · percentage of participants
Percentage of Participants With Medically Attended Adverse Events (MAEs) Within 6 Months After Vaccination
percentage of participantsGBS6 5 Microgram With Aluminum PhosphateGBS6 5 Microgram Without Aluminum PhosphateGBS6 10 Microgram With Aluminum PhosphateGBS6 10 Microgram Without Aluminum PhosphateGBS6 20 Microgram With Aluminum PhosphateGBS6 20 Microgram Without Aluminum PhosphatePlacebo
Percentage of Participants With Medically Attended Adverse Events (MAEs) Within 6 Months After Vaccination21.2 (11.1 to 34.7)23.1 (12.5 to 36.8)28.8 (17.1 to 43.1)19.2 (9.6 to 32.5)34.6 (22.0 to 49.1)26.9 (15.6 to 41.0)34.6 (22.0 to 49.1)
SecondaryGBS6 Serotype-Specific Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) at 1 Month After Vaccination

Serotypes used for evaluation were: Ia, Ib, II, III, IV, and V.

Time frame:
1 month after vaccination
Reported as:
Geometric mean · Microgram per milliliter
GBS6 Serotype-Specific Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) at 1 Month After Vaccination
Microgram per milliliterGBS6 5 Microgram With Aluminum PhosphateGBS6 5 Microgram Without Aluminum PhosphateGBS6 10 Microgram With Aluminum PhosphateGBS6 10 Microgram Without Aluminum PhosphateGBS6 20 Microgram With Aluminum PhosphateGBS6 20 Microgram Without Aluminum PhosphatePlacebo
Ia30.880 (13.301 to 71.691)20.341 (8.533 to 48.486)24.723 (10.577 to 57.785)41.826 (17.740 to 98.613)21.125 (10.121 to 44.094)17.829 (7.542 to 42.149)0.755 (0.372 to 1.536)
Ib2.060 (0.891 to 4.762)2.051 (0.952 to 4.417)3.174 (1.368 to 7.365)3.639 (1.426 to 9.289)2.742 (1.102 to 6.820)1.948 (0.785 to 4.836)0.034 (0.019 to 0.059)
II31.851 (17.303 to 58.630)21.919 (11.544 to 41.618)26.980 (14.586 to 49.904)57.011 (31.917 to 101.832)37.258 (20.764 to 66.853)31.786 (17.490 to 57.770)0.187 (0.126 to 0.279)
III5.683 (3.002 to 10.760)4.531 (2.290 to 8.965)4.979 (2.346 to 10.571)12.806 (6.221 to 26.365)5.559 (2.724 to 11.345)3.766 (1.887 to 7.517)0.081 (0.054 to 0.122)
IV2.915 (1.712 to 4.964)5.149 (2.913 to 9.102)4.924 (3.077 to 7.879)4.908 (2.890 to 8.336)4.303 (2.605 to 7.107)7.018 (4.518 to 10.903)0.046 (0.027 to 0.078)
V2.985 (1.346 to 6.619)3.368 (1.477 to 7.679)4.702 (2.033 to 10.878)5.142 (2.403 to 11.005)3.991 (1.984 to 8.031)6.760 (3.230 to 14.146)0.143 (0.084 to 0.244)

Adverse events

Collected over Local reactions and systemic events: within 14 days after vaccination on Day 1 and all AEs other than local reactions and systemic events: within 6 Months after vaccination on Day 1. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GBS6 5 Microgram With Aluminum Phosphate0/52 (0%)1/52 (1.9%)40/52 (76.9%)
GBS6 5 Microgram Without Aluminum Phosphate0/52 (0%)0/52 (0%)35/52 (67.3%)
GBS6 10 Microgram With Aluminum Phosphate1/52 (1.9%)1/52 (1.9%)39/52 (75%)
GBS6 10 Microgram Without Aluminum Phosphate0/52 (0%)0/52 (0%)36/52 (69.2%)
GBS6 20 Microgram With Aluminum Phosphate0/52 (0%)1/52 (1.9%)41/52 (78.8%)
GBS6 20 Microgram Without Aluminum Phosphate0/52 (0%)0/52 (0%)36/52 (69.2%)
Placebo0/52 (0%)0/52 (0%)35/52 (67.3%)
Most frequent serious events
Most frequent serious events
EventGBS6 5 Microgram With Aluminum PhosphateGBS6 5 Microgram Without Aluminum PhosphateGBS6 10 Microgram With Aluminum PhosphateGBS6 10 Microgram Without Aluminum PhosphateGBS6 20 Microgram With Aluminum PhosphateGBS6 20 Microgram Without Aluminum PhosphatePlacebo
Diabetic ketoacidosisMetabolism and nutrition disorders1/520/520/520/520/520/520/52
Completed suicidePsychiatric disorders0/520/521/520/520/520/520/52
MetrorrhagiaReproductive system and breast disorders0/520/520/520/521/520/520/52
Most frequent other events
Showing 10 of 15
Most frequent other events
EventGBS6 5 Microgram With Aluminum PhosphateGBS6 5 Microgram Without Aluminum PhosphateGBS6 10 Microgram With Aluminum PhosphateGBS6 10 Microgram Without Aluminum PhosphateGBS6 20 Microgram With Aluminum PhosphateGBS6 20 Microgram Without Aluminum PhosphatePlacebo
Injection site painGeneral disorders28/5217/5225/5220/5227/5213/528/52
FatigueGeneral disorders22/5217/5218/5214/5226/5220/5218/52
HeadacheNervous system disorders21/5219/5217/5220/5221/5216/5222/52
MyalgiaMusculoskeletal and connective tissue disorders9/5213/5210/5210/5210/5212/5210/52
DiarrhoeaGastrointestinal disorders7/5211/527/5211/5211/529/526/52
Nausea/vomitingGastrointestinal disorders7/523/526/529/525/526/5211/52
ArthralgiaMusculoskeletal and connective tissue disorders7/525/527/525/527/526/523/52
Upper respiratory tract infectionInfections and infestations1/520/523/521/524/526/523/52
SinusitisInfections and infestations4/522/522/521/522/520/522/52
InfluenzaInfections and infestations0/520/522/520/520/520/523/52

Baseline characteristics

Safety population included all participants who received either GBS6 vaccine or placebo.

Age, Continuous
Age, Continuous(years)GBS6 5 Microgram With Aluminum PhosphateGBS6 5 Microgram Without Aluminum PhosphateGBS6 10 Microgram With Aluminum PhosphateGBS6 10 Microgram Without Aluminum PhosphateGBS6 20 Microgram With Aluminum PhosphateGBS6 20 Microgram Without Aluminum PhosphatePlaceboTotal
Mean32.9 ± 8.4334.7 ± 9.3532.8 ± 8.3131.9 ± 8.1033.2 ± 8.6730.5 ± 8.2532.8 ± 8.7432.7 ± 8.57
Sex: Female, Male
Sex: Female, Male(Participants)GBS6 5 Microgram With Aluminum PhosphateGBS6 5 Microgram Without Aluminum PhosphateGBS6 10 Microgram With Aluminum PhosphateGBS6 10 Microgram Without Aluminum PhosphateGBS6 20 Microgram With Aluminum PhosphateGBS6 20 Microgram Without Aluminum PhosphatePlaceboTotal
Female35413233353743256
Male1711201917159108
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)GBS6 5 Microgram With Aluminum PhosphateGBS6 5 Microgram Without Aluminum PhosphateGBS6 10 Microgram With Aluminum PhosphateGBS6 10 Microgram Without Aluminum PhosphateGBS6 20 Microgram With Aluminum PhosphateGBS6 20 Microgram Without Aluminum PhosphatePlaceboTotal
Hispanic or Latino242251521
Not Hispanic or Latino50475049475147341
Unknown or Not Reported01010002
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)GBS6 5 Microgram With Aluminum PhosphateGBS6 5 Microgram Without Aluminum PhosphateGBS6 10 Microgram With Aluminum PhosphateGBS6 10 Microgram Without Aluminum PhosphateGBS6 20 Microgram With Aluminum PhosphateGBS6 20 Microgram Without Aluminum PhosphatePlaceboTotal
White44414641454644307
Black or African American595844742
Other21022209
Asian10111015
Native Hawaiian or other Pacific Islander01000001
08

Study locations

4 sites
  • Clinical Research Atlanta
    Stockbridge, Georgia 30281, United States
  • Kentucky Pediatric / Adult Research
    Bardstown, Kentucky 40004, United States
  • J. Lewis Research, Inc. / Foothill Family Clinic
    Salt Lake City, Utah 84109, United States
  • J. Lewis Research, Inc. / Foothill Family Clinic South
    Salt Lake City, Utah 84121, United States
09

References and documents

Publications

  • Absalon J, Segall N, Block SL, Center KJ, Scully IL, Giardina PC, Peterson J, Watson WJ, Gruber WC, Jansen KU, Peng Y, Munson S, Pavliakova D, Scott DA, Anderson AS. Safety and immunogenicity of a novel hexavalent group B streptococcus conjugate vaccine in healthy, non-pregnant adults: a phase 1/2, randomised, placebo-controlled, observer-blinded, dose-escalation trial. Lancet Infect Dis. 2021 Feb;21(2):263-274. doi: 10.1016/S1473-3099(20)30478-3. Epub 2020 Sep 3. PubMed 32891191 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2017 to primary completion in Jun 2018, 12 months.

Results were first posted in Jul 2019, 1 year after primary completion.

Of 12 phase 2 interventional studies under Streptococcal Infections, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 25. This study's 12 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2017
First posted
May 31, 2017
StartActual
Jun 5, 2017
Primary completionActual
Jun 25, 2018
CompletionActual
Jun 25, 2018
Results first posted
Jul 2, 2019
Last update
Jul 2, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03170609
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
May 31, 2017
Start date
Jun 5, 2017
Primary completion
Jun 25, 2018
Completion
Jun 25, 2018
Results posted
Jul 2, 2019
Last update
Jul 2, 2019

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion